Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Spermosens AB ("Spermosens" or the "Company") announces the second interim results from its ongoing clinical study at the Reproductive Medicine Center (RMC) in Malmö. The study is designed to validate the diagnostic value of the company's patented JUNO-Checked system and is progressing according to plan. The data confirm and strengthen the findings from the first interim analysis released in December 2024. Specifically, the results continue to demonstrate correlation between the JUNO binding and fertility outcomes.
To date, the study has successfully recruited 52 couples, with JUNO binding analysis completed in 37 of these cases. The interim results show that a higher JUNO binding, reflecting the sperm cells' ability to bind to the egg, is positively correlated with better fertilization and pregnancy outcomes. In contrast, cases with very low or absent JUNO binding do not result in fertilization, further reinforcing the clinical relevance of the JUNO-Checked technology as a diagnostic tool in assisted reproductive treatments.
These findings provide growing evidence that the JUNO-Checked system can help identify sperm related factors in unexplained infertility. Particularly in couples with no identifiable reproductive issues, where standard semen parameters are within normal ranges, and yet fertilization and pregnancy repeatedly fail.
Tore Duvold, CEO of Spermosens, comments: "We are encouraged by these latest findings from this second interim analysis, which further validates the diagnostic potential of JUNO-Checked. These results align with our previous interim data, reinforcing the important role of sperm-egg binding capacity in fertility outcomes. The study is progressing according to plan, and we remain committed to advancing our technology toward clinical adoption in collaboration with established partners in the ART market."
Dr Ingela Liljeqvist Soltic, Embryologist & Lab Director at RMC and Principal Study Investigator, comments: "Infertility remains a significant challenge for many couples undergoing assisted reproductive treatments, and there is a clear need for more precise diagnostic tools to improve outcomes. The JUNO-Checked technology provides valuable insights into sperm-egg interaction, which could help clinicians better tailor fertility treatments and enhance the chances of successful conception. These interim results support its potential role in optimizing patient care and addressing a critical gap in fertility diagnostics."
The clinical study continues to generate valuable insights into the role of sperm binding capacity in assisted reproductive treatments. The latest results further strengthen the predictive value of JUNO-Checked, reinforcing its potential as a key tool for fertility diagnostics in IVF clinics and sperm banks. The ambition is to complete the study in 2025, delivering solid clinical evidence that supports the diagnostic value of the JUNO-Checked technology and lay the ground for securing licensing agreements with established partners in the ART market.
Supported by a recent strategic investment of SEK 10.8 million, Spermosens has established a stable financial foundation to advance its priorities, including clinical validation, technical enhancements and commercialization through strategic partnerships. The appointment of Dr. Jaime Castillo-León as Chief Commercial Officer further enhances the company's capabilities, while the recently announced collaborations with Scalania, part of the UNITY Innovation Alliance, will support the regulatory and market access efforts. With a clear path toward cash flow positivity in the second half of 2026, the company is well-positioned to create value for patients, partners and shareholders.
For further information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com
Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com